The Silent Killer: Recent Advances in Cardiovascular Disease There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170303 For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

1. The Silent Killer: Recent Advances in Cardiovascular Disease
There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research
report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of
cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace.
Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to
limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative
therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry
and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a
commercial time bomb where the risk/reward ratio for any company willing to participate needs to be
carefully considered.
This report provides you with a systematic appraisal into the current and future CV market, including...
A detailed review of the leading brands and how they are being positioned in the market, in addition to the
potential impact of generics
Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical
development where proof of concept data has been established Review of products that are ‘Waiting in
the Wings’ in early-stage clinical development where Point-of-Care data is being gathered Analysis of
the potential of ‘Long Shots’ which represent new and innovative products where the scientific
rationale has yet to be fully tested Antilipidemics
The lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and
triglycerides (TGs) has been shown to reduce the chance of a heart attack and death in people who have an
elevated risk of developing heart disease or who already have heart disease. Several drug classes are currently
available to treat a range of lipid disorders; each has a different mechanism of action, safety profile and impact
on blood lipid profiles to different degrees.
Key drugs covered by the report include
Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc... Recent generics
- Atorvastatin, etc... Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen),
Anacetrapid (Merck & Co), etc... Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr
Reddy), etc... Long shots - ALN PCS (Alnylam/The Medicine Company), etc... Just some of the key questions
answered include Why are statins the gold stand in lipid lowering therapies and which is the most effective
at lowering LDL-C? Will AstraZeneca’s Crestor win its fight for supremacy before generic
rosuvastatin reaches the market? Why are PCSK9 inhibitors important to cardiologists and which drugs are
leading the field? Kynamro approved in the US but not in Europe… what next? What new HDL-C
modulating therapies are in development? What new products are in development from BMS/Simcere; Dr
Reddy and DezimaPharma?
N/a
Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most
comprehensive collection of market research reports. Marketresearchreports.biz services are especially
designed to save time and money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription access and consulting services.
We serve all sizes and types of companies spanning across various industries.
Contact:
The Silent Killer: Recent Advances in Cardiovascular Disease

2. M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.com
Website: www.marketresearchreports.biz
The Silent Killer: Recent Advances in Cardiovascular Disease